BOSULIF: payments to doctors
Payments that named BOSULIF as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.1M
- Providers
- 7,213
- Transactions
- 27,144
- Average per transaction
- $39
The per-transaction average — $39 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,213 providers the average total is $146, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Pfizer | $1,004,320 | 95.5% |
| Laboratorios Pfizer LDA. | $24,535 | 2.3% |
| Hikma Pharmaceuticals USA | $16,426 | 1.6% |
| Whitehall International Inc | $2,250 | 0.2% |
| Pfizer Chile S.A. | $2,222 | 0.2% |
| PBG Puerto RICO LLC | $1,466 | 0.1% |
| Array Biopharma Inc | $937 | 0.1% |